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ABSTRACT
Isoniazid (INH), one of the major antituberculosis drugs, is metabolized by acetylation. 
Previously study proved the significant differences of serum INH concentration between 
subject with fast and slow acetylation status. However, the correlation of acetylation 
status with treatment outcome after fixed-dose combination antituberculosis therapy 
(FDC-ATT) was not explained. The aim of this study was to evaluate the influence of 
acetylation status on the treatment outcome and the serum INH concentrations in the 
adult tuberculosis patients underwent FDC-ATT. A cross sectional study was carried 
out on 31 tuberculosis patients. Acetylation status was measured by spectrophotometer 
and serum INH concentration was measured by high performance liquid chromatography 
(HPLC). Sputum conversion assay was conducted by Ziehl Nelsen method. t-Test, chi 
square, Mann-Whitney, and Fisherman were used to analyze the data. The proportion of 
the fast acetylator was 61.3%, whereas the slow acetylator was 38.7%. The proportion 
of success and failure sputum conversion were 83.9% and 16.1%, respectively. The 
mean serum INH concentration in the fast acetylator groups (1.52 ± 0.15 µg/mL) was 
significantly lower than that in the slow acetylator groups (3.84 ± 0.35 µg/mL). The 
failure conversion risk of the fast acetylator group was about two folds higher than 
the slow acetylator group, although it was not significantly different  (RR=2.53; 95% 
CI=0.32-20.00; p>0.05). Moreover, the mean serum INH concentration in success 
(2.46 ± 0.31 µg/mL) and failure (1.89 ± 0.20 µg/mL) sputum conversion was not 
significantly different (p>0.05). In conclusion, the acetylation status does not influence 
the sputum conversion in adult tuberculosis patients after FDC-ATT although the serum 
INH concentration on slow acetylation status is higher than that fast acetylation status.   
ABSTRAK
Isoniazid (INH) merupakan salah satu obat antituberkulosis utama yang metabolismenya 
melalui asetilasi. Pada penelitian sebelumnya dilaporkan ada perbedaan kadar INH serum 
pada orang dengan asetilator cepat dan lambat. Namun demikian hubungan antara status 
asetilasi dengan keberhasilan terapi penderita tuberkulosis (TB) yang mendapat obat 
antituberkulosis kombinasi dosis tetap (OAT-KDT) belum dijelaskan secara rinci. Tujuan 
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penelitian ini adalah untuk mengkaji pengaruh status asetilasi terhadap keberhasilan 
terapi dan kadar INH serum penderita TB paru dewasa. Rancangan penelitian adalah 
potong lintang dengan subjek penelitian sebanyak 31 orang penderita TB. Status asetilasi 
ditetapkan dengan spektrofotometer dan kadar INH serum dengan high performance 
liquid chromatography (HPLC). Pemeriksaan sputum dilakukan dengan metode Ziehl 
Nelsen. Analisis statistik dengan uji t, Chi-square, Mann-Whitney, dan Fisherman. Proporsi 
status asetilasi cepat sebesar 61,3% sedangkan asetilator lambat 38,7%. Proporsi 
keberhasilan konversi sputum 83,9% dan gagal konversi 16,1%. Rerata kadar INH serum 
pada asetilator lambat (3,84+0,34 µg/mL) lebih tinggi secara nyata dibandingkan pada 
asetilator cepat (1,52+0,15 µg/mL) (p<0,05). Risiko gagal konversi pada kelompok 
asetilator cepat sekitar 2,53 kali dibandingkan pada asetilator lambat, meskipun tidak 
bermakna secara nyata (RR=2,53; 95%CI=0,32-20,00; p>0,05). Rerata kadar INH 
serum pada kelompok berhasil konversi yaitu 2,46+0,31 µg/mL tidak berbeda nyata 
dengan kelompok gagal konversi yaitu 1,89+0,20 µg/mL (p>0,05). Dapat disimpulkan, 
status asetilasi tidak mempengaruhi konversi sputum pada penderita TB dewasa yang 
mendapat OAT-KDT meskipun kadar serum INH pada status asetilasi lambat lebih tinggi 
dari pada status asetilasi cepat.   
Keywords: acetylation status – isoniazid level - success of therapy - conversion  sputum 
- intensive phase treatment - tuberculosis
INTRODUCTION
Tuberculosis (TB) is an infectious disease 
caused by Mycobacterium tuberculosis (M. 
tuberculosis). The spread of M. tuberculosis 
occurs from person to person primarily through 
droplet transmission in air.1,2 Tuberculosis is a 
major health problem in the world, especially 
in developing countries. Approximately 
one third of the world’s population has been 
infected with M. tuberculosis with the main 
source of transmission from TB patients basil 
hold acid (BTA) positif.3
In 2007, World Health Organization 
(WHO) reported that approximately 9.27 
million new cases of TB were reported. This 
incidence increased from the previous year of 
9.24 million new cases in 2006 and 8.3 million 
new cases in 2000. Mortality due to TB is also 
reported to be very high. In 2007, 1.3 million 
deaths from TB or 20 deaths per 100,000 
population were reported. Approximately 
90% of the total deaths occur in developing 
countries. According to WHO, 22 countries 
are classified as high-burden countries for TB, 
included Indonesia.4
Indonesia ranks third on the list of high-
burden tuberculosis countries in the world 
after India and China with the number of TB 
patients about 10% of the total number of 
TB patients in the world. In 2004 there were 
539,000 new cases per year and 101,000 
deaths occur people from TB in Indonesia. 
The prevalence rate of smear positive TB in 
the National was 110 per 100,000 population.3 
The prevalence of TB in the Yogyakarta and 
Bali reported the lowest at 68 per 100,000 
people. Pulmonary TB disease morbidity in 
Yogyakarta was 3.18 per 100,000 penduduk.5
Tuberculosis become more serious 
health problem with the increasing of Human 
Immunodeficiency Virus (HIV)/Acquired 
Immunodeficiency Syndrome (AIDS) cases.6 
Another issue that exacerbates tuberculosis is 
the emergence of multiple drug resistance TB 
(MDR-TB), which can lead to cases of TB more 
difficult to treat.7 Resistance to antituberculosis 
mainly due to the inadequateuse use of 
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drugs . Inadequate therapy can be caused by 
inappropriate management therapy.8  Since 
1995 TB treatment has been carried out using 
Directly Observed Treatment Shortcourse 
(DOTS) which is given in two stages, intensive 
and continuation phases. At the end of the 
intensive phase and continuation phase, a 
patient sputum examination is conducted and 
evaluated. Successful treatment is considered 
if the patient sputum smear negatif in a 
microscopic examination is observed.3
Isoniazid (INH) is one of the main TB drugs 
which is generally given in the form of oral 
antituberculosis (OAT) drug in combination 
with others. Isoniazid has bacteriostatic 
and bactericidal activities. The  metabolism 
of INH is affected by a drug metabolizing 
enzymes in the liver that is N-acetyltransferase 
2 (NAT2) through acetylation reaction. Based 
on the reaction of NAT2 acetylation by this 
person can be categorized as fast acetylators 
or lambat.9,10
Individuals with rapid acetylator 
phenotypes must take INH doses greater 
than those with slow acetylator phenotypes.11 
Meanwhile another study proved that low 
serum INH concentrations was observed in 
individuals with rapid acetylator phenotypes.10 
The mean blood INH concentration 2 hours 
after INH administration in individuals with 
slow acetylator phenotypes was two times 
higher than those with rapid acetylator 
phenotypes.12 Other studies also reported an 
association between INH acetylators status 
with outcome of TB treatment with once-
weekly INH and rifapentine.13
NAT2 gene polymorphisms that determine 
the acetylator phenotypes of INH has been 
known to vary at different race or ethnicity. 
In the Indonesian population known to 65.4% 
of people classified as fast acetylators, and 
35.6% are slow acetylators.14 This study 
was conducted to evaluate the influence of 
acetylator phenotypes of tuberculosis patients 
on the serum INH concentration and sputum 
conversion after intensive phase therapy.
MATERIALS AND METHODS
This was an observational study using 
cross sectional design involving 31 subjects 
who met the inclusion and exclusion criteria. 
The  inclusion criteria were adult patients with 
pulmonary TB (aged over 18 years) smear 
positive TB new cases, received TB treatment 
category 1 (2HRZE / 4H3R3), and willing 
to participate in the study. The exclusion 
criteria were subjects with diabetes mellitus, 
suffer from liver dysfunction, had a history of 
allergy to sulfa drugs, could not communicate 
well, not willing to follow the course of TB 
treatment with DOTS strategy. Protocol of 
the study was approved by the Medical and 
Health Research Ethics Committee, Faculty 
of Medicine, Universitas Gadjah Mada, 
Yogyakarta. 
Protocol of Study
Acetylation status determination
The acetylators phenotypes were 
determined  using sulphadimidine according 
to the method developed by Rao et al.15 
Patients were given sulphadimidine 500 mg 
orally early in the morning on empty stomach. 
They were not allowed to take anything for the 
next two hours. Urine sample were collected 
before and 6 hours after sulphadimidine 
administration. Free and total sulphadimidine 
in the urine were determined by using 
spectrophotometer (Spectronic 20D + Thermo 
Fiher Scientific) at a λ of 540 nm. Acetylation 
status was determined based on the ability to 
produce the acetylated sulphadimidine (total 
minus free sulphadimidine) and expressed 
as a percentage of the total sulphadimidine. 
Patient was considered as rapid acetylator if 
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the acetylated sulphadimidine was >70% and 
as slow acetylator if it was <70%. 
Measurement of serum INH concentration
Blood sample was taken before (day 0) 
and at the end of the intensive of treatment 
(day 56 of treatment). Three mL blood sample 
was taken from the median cubital vein two 
hours after OAT administration. The blood 
sample was then centrifuged at 3000 rpm, 
serum was taken and stored at -80 oC until 
analysed. Serum INH concentration was 
determined by using High Performance Liquid 
Chromatography (HPLC) in the Integrated 
Research and Testing Laboratory, Universitas 
Gadjah Mada, Yogyakarta. A simple extraction 
was conducted by protein precipitation with 
150 µL of trichloroacetic acid 15% in 300 µL 
serum. The mixture was then vortexed for two 
min and centrifuged at 3000 rpm for 10 min. 
The supernatant was collected and 20 µL was 
injected into the HPLC system. The stationary 
phase was Novapak® C18 column (150 x 3.9 
mm, 3 microns). The mobile phase consisted 
of 0.05 M sodium dihydrogen phosphate and 
acetonitrile (97: 3) and set at a flow rate of 
1 mL/min at room temperature. The detection 
was performed at λ of 280 nm. 
Sputum examination
Sputum was spread evenly over the 
central area of the slide which was air dried 
for about 30 min and heat fixed. The sputum 
slide was then flooded with Ziehl Neelsen 
(ZN) stain which was then heated to dry, kept 
for 5 min and washed with aquadest.  The slide 
was then flooded with 3 mL of concentrated 
hydrochloric acid and 97 mL of ethanol 95% 
to decolourise the ZN stain and washed with 
aquadest.  Thereafter, the slide was flooded 
with 0.3 g of methylene blue and 100 mL of 
aquadest for 2 min. The slide was air dried at 
room temperature and viewed on a microscope 
under oil immersion for presence of acid-fast 
bacilli. The bacilli were stained red and the 
background material was stained blue.
Statistical analysis
Data were presented as mean ± standard 
deviation (SD) or percentage and analyzed 
using SPSS software version 16. Numerical 
data were compared by using t-test or Mann-
Whitney U test, whereas categorical data 
were compared by using Chi-square test or 
Fisher exact test. To determine the relative 
risk (RR) conversion failures in the rapid and 
slow acetylators group, 2 x 2 table relative 
risk analysis (Epi Info Program) at the 95% 
confidence interval was performed.
RESULTS
Among 34 subjects who met the inclusion 
criteria, only 31 patients completed the study. 
One subject can not be included until the end 
of the study period due to suffer from liver 
dysfunction as characterized by high levels 
of serum transaminases in early therapy and 
two subjects do not abide taking the drugs. 
The characteristics of subjects are presented 
in TABLE 1.
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The proportion of subjects with fast 
acetylators phenotype status was 61.3%, 
and 38.7% was people with slow acetylators 
TABLE 2. Patient characteristics based acetylation status (n=31)
Characteristics
Acetylation status
p
Slow (n=12) Fast (n=19)
Age (mean ± SD year) 42.1 ± 13.2 45.5 ± 14.3 0.518
Sex (%)
Male 9 (75.0) 15 (78.9)
1.00
Female 3 (25.0) 4 (21.1)
Weight  (mean ± SD kg) 49.3 ± 4.9 49.6 ± 6.5 0.884
Height  (mean ± SD cm) 165 ± 7 163 ± 6 0.251
Body Mass Index (mean ± SD) 18.0 ± 2.1 18.7 ± 1.9 0.224
Nutritional Status (%)
Normal 3 (25) 9 (47.4)
0.129
Low 9 (75) 10 (52.6)
Smoker (%)
Yes 8 (66.7) 12 (63.2)
0.842
No 4 (33.3) 7 (36.8)
Characteristic Value
Age (mean ± SD year) 44.2 ± 13.7
Sex [n (%)]
Male 24 (77.4)
Female 7 (22.6)
Weight  (mean ± SD kg) 49.5 ± 5.8
Height  (mean ± SD cm) 164  ± 6
Body Mass Index (mean ± SD) 18.4 ± 2.0
Nutritional Status (%)
Normal 13 (41.9)
Low 18 (58.1)
Smoker [n (%)]
Yes 20 (64.5)
No 11 (35.5)
INH dose [n (%)]
225 (3 FDC-ATT) 24 (77.4)
300 (4 (FDC-ATT) 7 (22.6)
TABLE 1. Patients characteristic (n=31)
status. Characteristics of patients in the fast or 
slow acetylators did not show any statistically 
significant difference (TABLE 2).
J Med Sci, Volume 50, No. 1, 2018 January: 59-69
64
TABLE 3. Patient characteristics based on sputum conversion (n=31)
Characteristics
Acetylation status
pSuccess 
(n=26)
Failure 
(n=5)
Age (mean ± SD year) 42.3 ± 13.1 54.0 ± 14.0 0.083
Sex [n (%)]
Male 21 (80.8) 3 (60.2)
0.562
Female 5 (19.2) 2 (40.0)
Weight  (mean ± SD kg) 49.9 ± 6.0 47.2 ± 5.2 0.646
Height  (mean ± SD cm) 164 ± 6 161 ± 6 0.333
Body Mass Index (mean ± SD) 17.7 ± 2.0 18.2 ± 2.1 0.774
Nutritional Status [n (%)]
Normal 11 (42.3) 3 (60.0)
1.000
Low 15 (57.7) 2 (40.0)
Smoker [n (%)]
Yes 18 (69.2) 2 (40.0)
0.317
No 8 (30.8) 3 (60.0)
Acetylation status [n (%)]
Fast 15 (57.7) 4 (80) 0.624
Slow 11 (42.3) 1 (20)
INH concentration (mean±SEM µg/mL) 22.88±0.51 1.89±0.26 0.519
INH dose [n (%)]
225 mg (3 FDC-ATT) 19 (73.1) 5 (100)
0.562
300 mg (4 FDC-ATT) 7 (26.9) 0 (0)
Zero in serum INH concentration was 
observed before treatment begin. After 
complete treatment (day 56), the mean serum 
INH concentration was 2.72 µg/mL (ranged 
from 0.53 to 13.32 µg/mL).  Most individuals 
who failed sputum conversions (80%) had 
a fast acetylators phenotype, whereas in 
the group succeeded only 57.7% sputum 
conversion. But this was not statistically 
significant (Fisher’s exact test, p> 0.05). 
Based on the analysis of the 2x2 table (Epi 
Info Program) obtained RR = 2.53 (95% CI: 
0.32 to 20.00). Although the risk of conversion 
failure in fast acetylators group seen 2 times 
greater than the slow acetylators, but not 
statistically significant (TABLE 4). 
Most patients had successful sputum 
conversion  (83.9%), whereas only 16.1%  had 
failure sputum conversion. Characteristics of 
patients based on the success and failure of 
sputum conversion are presented in TABLE 3.
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TABLE 4. Conversion failure risk based on acetylation status (n=31)
Acetylation status
   Sputum conversion
Total x2, p RR (95% CI)
Success Failure
Fast 4 15 12 0.342 0.32-20.00
Slow 1 11 19
Total 5 26 31
The mean serum INH concentration in the 
slow acetylators patients (4.63 µg/mL) was 
much higher than fast acetylators (1.52 µg/
mL). But in the group of slow acetylators, one 
subject had extreme INH concentration until 
13.32 µg/mL. After extreme data excluded, 
the mean INH concentration of the slow 
acetylators (3.84 ± 0.34 µg/mL) was two 
times higher than that the rapid acetylators 
(1.52 ± 0.15 µg /mL) (p <0.05 ) as shown on 
TABLE 5.
TABLE 5. Serum INH concentration in the fast and slow acetylation status (n=30)
Acetylation status n
Serum INH concentration (µg/mL)
Mean SEM 95% CI Min-Max p
Fast 19 1.52 0.15 1.20-1.83 0.53-2.54
0.000
Slow 11 3.84 0.34 3.07-4.61 2.29-5.01
The mean INH concentration in the 
subjects with failed in sputum conversions 
(1.89 ± 0.20  µg/mL) was significantly lower 
than the subjects with success in sputum 
conversions (2.88 ± 0.51  µg/mL) (p<0.05). 
One subject with extreme INH concentration 
was found in the subjects with success in 
sputum conversion. After subjects with 
extreme INH concentration excluded, the 
mean INH concentration between the subjects 
with success in sputum conversion  (2.46 ± 
0.31 µg/mL) was similar to those with failed 
in sputum conversion (1.89 ± 0.20 µg/mL) 
(p>0.05). 
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FIGURE 1. Serum INH concentration  based on sputum conversion (n=30)
Most subjects (77.4%) received 3 FDC-
ATT tablets (225 mg INH), and 22.6% 
received 4 FDC-ATT tablets (300 mg). The 
mean serum INH concentration in the group 
receiving 225 mg or 3 tablets FDC-ATT was 
no higher than those receiving 300 mg or 4 
tablets FDC-ATT (2.55 ± 0.30 µg/mL vs. 1.63 
± 0.31 µg/mL; Mann-Whitney test p > 0.05) 
(TABLE 6).
TABLE 6. Serum INH concentration based on INH dose (n=30)
Dose of INH n Mean SEM 95% CI Min-Max p
225 mg 24 2.55 0.30 1.92-3.18 0.59-5.05
0.147
300 mg 6 1.63 0.31 0.83-2.44 0.53-2.67
DISCUSSION
The proportion of rapid acetylation status 
(61.3%) was higher than that slow acetylation 
status (38.7%) in this study. This proportion 
was similar with the results reported in the 
previous study conducted in the Community 
Health Care and Center for Pulmonary Disease 
Treatment (BP4) in Yogyakarta which found 
64% of patients were rapid acetylation status 
and 36% of patients were slow acetylation 
status.16 Furthermore, it was estimated that 
approximately 2/3 (66.67%) of the Indonesian 
people classified as rapid acetylation status 
and 1/3 (33.33%) as slow acetylation status.14 
The mean serum INH concentration on 31 
patients two hours after drug administration 
was 2.72 ± 0.43 µg/mL ranged from 0.53 to 
13.32 µg/mL and the median was 2.21 µg/
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mL in this study. Serum INH concentration on 
TB patients after treatment has been reported 
in the previous studies. A therapeutic drug 
monitoring study on TB patients conducted 
in Virginia, USA reported that the median 
of serum INH concentration two hours 
after drugs administration was 1.9 µg/mL 
(interquartile range 1.1-3.5 µg/mL).17 Another 
study conducted on TB patients in Turkey 
found the mean serum INH concentration two 
hours after OAT treatment was 3.83 ±2.09 µg/
mL.18 Furthermore, study conducted on TB 
patients in Alberta, Canada found the mean 
serum INH concentration was 4.13 ± 3.9 µg/
mL.19
The success of TB treatment  is proven 
by the sputum conversion from smear positive 
to smear negative at the end of the intensive 
phase of treatment. In this study TB treatment 
success rate achieved 83.9%, while the failure 
rate was 16.1%.  The TB treatment success rate 
has been reported from various regions. The 
Province Health Office in Yogyakarta Special 
Region reported that the TB treatment success 
rate achieved 87%.20 A study conducted in UK 
demonstrated the TB treatment success rate 
was 87.%.21 However, in 2013 in America and 
European regions the TB treatment success 
rate was 75%, whereas in Malaysia was 67% 
less than the 85% success target set by the 
WHO. Globally, the TB treatment success rate 
for people newly diagnosed with TB was 86% 
in 2013.22, 23 
The TB treatment failure on the rapid 
acetylator group (80% or 4 people) was higher 
compared to on the slow acetylation status 
group (20% or 1 people). The RR of failure 
in the sputum conversion of fast acetylation 
status group was two times higher than the 
slow acetylation status group although it was 
not significantly different.  This results is 
different from the previous study that showed 
a relationship between acetylation status and 
outcome of TB treatment with once-weekly 
INH and rifapentine.13 The different of dosage 
regimen and patient compliance may cause 
the different of these results. 
The mean serum INH concentration of 
slow acetylation status group (3.84 ± 0.34 µg/
mL) was higher than that rapid acetylation 
status (1.52 ± 0.15 µg/mL). The higher serum 
INH concentration of slow acetylation status 
compared to that rapid acetylation status was 
also reported in the previous studies.  Schaaf et 
al.12 reported the serum INH concentration of 
slow acetylation status (8.6 µg/mL) was two-
old higher than that rapid acetylation status 
(3.94 µg/mL). Furthermore, Conte et al.24 
also reported the serum INH concentration of 
slow acetylation status (1.1 ± 0.8 µg/mL) was 
higher than that rapid acetylation status (0.5 ± 
0.6 µg/mL). 
The mean serum INH concentration in 
the patients with failed in sputum conversions 
(1.89 ± 0.20  µg/mL) was significantly lower 
than the subjects with success in sputum 
conversions (2.46 ± 0.31  µg/mL). However, 
it was not significantly different (p>0.05). It 
was reported that effective of tuberculostatic 
minimal concentration of INH range from 
0.025 to 0.05 µg/mL, whereas the therapeutic 
INH concentration range from 0.5 to 2.0 µg/
mL.25-27 In this study, the mean serum INH 
concentration in the both patients with filed 
and success in sputum conversions met the 
therapeutic INH concentration that indicated 
serum INH concentration did not influence 
the sputum conversion. No different in serum 
INH concentration in the patients with failed 
and success in sputum conversions nor in the 
patients with delays and avoid delay in sputum 
conversions were also reported in the previous 
study.25
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CONCLUSIONS
Adult pulmonary TB patient with rapid 
acetylation status has lower serum INH 
concentrations than slow acetylation status. 
However, these serum INH concentrations are 
still within the therapeutic INH concentration 
therefore the acetylation status does not affect 
the sputum conversion after the intensive 
phase of TB treatment.
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